New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 28, 2020 - CSL Behring announced the FDA approval of Haegarda (C1 esterase inhibitor [human]), for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.
Download PDF
Return to publications
